Delta and epsilon crystal forms of Imatinib mesylate
US7879860B2 · kind B2 · utility
1Cited by
1References
27Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 24, 2006 |
| Grant date | Feb 1, 2011 |
| Priority date | — |
| Expiry date | Aug 24, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the delta and epsilon crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2 -ylamino)phenyl]-benzamide (the compound of formula I, see below), certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.